Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Vascular Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Vascular Disorders
    Vascular Thoracic Stent Graft Proves Safe and Effective: Summary of the VALOR Trial - (DGNews)
    Statin Therapy Underused in Elderly Patients With Atherosclerosis - (DGNews)
    Newer CT Machines Effective in Detecting Coronary Artery Stenosis - (DGNews)
    TopAbstracts in Vascular Disorders 08/07/2008 - (DGNews)
    TopAbstracts in Vascular Disorders 07/24/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Vascular Disorders
    • Understanding Metabolic Dysfunction in HIV
    • Identifying Metabolic Dysfunction in Patients With HIV: Prevalence, Consequences, and Potential Mechanisms
    • Several Management Options Available for Metabolic Dysfunction in Patients With HIV
    • PVD: Controversies in Carotid, Renal and Peripheral Arterial Therapies
      Recognition and Management of Leg Disorders Across the Spectrum

      Webcasts/CME archive

       Recent cases - Vascular Disorders
        Unexpected Limited Chronic Dissection of the Ascending Aorta
        Mycobacterium Tuberculosis Aortic Graft Infection with Recurrent Hemoptysis: A Case Report
        Takayasu's Arteritis Presenting as a Dissecting Aortic Aneurysm History: A Case Report
        Aberrant Right Subclavian Artery and Calcified Aneurysm of Kommerell's Diverticulum: An Alternative Approach
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report

        Cases archive
          




        my personal edition > vascular disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Drug-Eluting Beads Fight Liver Cancer: Presented at ISET

        By Michael Casasnovas

        HOLLYWOOD, FL -- February 6, 2007 -- In a pilot study, 90% of patients with liver cancer infused with drug-eluting beads were alive more than 1 year later, researchers reported here at the 19th International Symposium on Endovascular Therapy (ISET).

        The beads were placed into tiny arteries that fed the cancer in a procedure known as transarterial chemoembolization of hepatocellular carcinoma with doxorubicin-loaded microspheres.

        "The potential benefit of hepatocellular carcinoma chemoembolization can be limited by the passage of the chemotherapeutic agent into the systemic circulation," said Johannes Lammer, MD, professor of radiology, University Hospital, Vienna, Austria.

        Dr. Lammer noted, the experimental treatment did not appear to cause major systemic adverse events.

        The 6-month efficacy, an objective tumor response of 44% to 56%, favorably compares with the published literature, he said.

        "The drug-eluting bead is a novel agent for chemoembolisation with a unique availability for loading doxorubicin. A slow release of doxorubicin has significant potential benefits," Dr. Lammer said in his oral presentation on February 1st.

        His study enrolled 30 patients, ages 44 to 82 years, all of whom were diagnosed with hepatocellular carcinoma. Patients were included in the trial if they had some preserved liver function yet were not candidates for resection, transplantation or percutaneous therapies. Patients also had to have a Karnofsky performance status score greater than 60; were expected to live more than 3 months, and were able to give informed consent.

        Treatment was administered at baseline and then at months 2 and 4. Patients underwent follow-up visits at 1, 3 and 6 months for evaluation of clinical status and for laboratory liver and blood tests.

        Among the 25 patients who were treated, 3 achieved a complete response using Response Evaluated Criteria in Solid Tumors (RECIST). Another 7 patients achieved a partial response and 5 achieved disease stabilization.

        Three patients died, including 1 of the patients who had achieved complete response at 6-month. That patient died from cholecystitis.

        Mean survival at the time of Dr. Lammer's presentation was 376 days, ranging from 334 days to 419 days.

        He said that 15 European centers in 5 countries are now enrolling 200 patients in "The Prospective Randomized Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (Precision V Study)."


        [Presentation title: Chemoembolization of HCC With Drug eluting Beads.]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send